ProQR to Present Results from Phase 1/2 Trial of QR-421a for Usher Syndrome Press release LEIDEN, Netherlands & CAMBRIDGE, Mass., March 17, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. March 17, 2021
ProQR Announces First Quarter 2023 Operating and Financial Results Press release Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1 Development of Axiomer® RNA base editing technology platform continues across multiple therapeutic areas Stre May 16, 2023